Varenicline for smoking cessation: A review of the literature
- 1 February 2009
- journal article
- review article
- Published by Elsevier in Current Therapeutic Research
- Vol. 70 (1) , 35-54
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Lack of Pharmacokinetic and Pharmacodynamic Interactions Between a Smoking Cessation Therapy, Varenicline, and Warfarin: An In Vivo and In Vitro Study1The Journal of Clinical Pharmacology, 2007
- Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aidNeuropharmacology, 2007
- Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- The neurobiological basis for partial agonist treatment of nicotine dependence: vareniclineInternational Journal Of Clinical Practice, 2006
- Annual smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 1997-2001.2005
- Molecular and Physiological Diversity of Nicotinic Acetylcholine Receptors in the Midbrain Dopaminergic NucleiJournal of Neuroscience, 2001
- Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settingsNicotine & Tobacco Research, 2001
- Addiction, Dopamine, and the Molecular Mechanisms of MemoryNeuron, 2000
- Nicotine and food induced dopamine release in the nucleus accumbens of the rat: Putative role of α7 nicotinic receptors in the ventral tegmental areaNeuroscience, 1998
- Molecular and Cellular Aspects of Nicotine AbuseNeuron, 1996